Cell Therapy News

The FDA granted fast track designation to ALLO-605, a chimeric antigen receptor T-cell therapy for adults with relapsed or refractory multiple myeloma.

Patients with relapsed or refractory large B-cell lymphoma who received second-line axicabtagene ciloleucel achieved significantly longer EFS than those who received standard of care, according to data released by the agent’s manufacturer.

Each 6-month decrease in exposure to immune checkpoint inhibitors nearly doubled the duration of response to therapy with lifileucel among patients with metastatic melanoma, according to long-term results of a phase 2 study.

The FDA granted orphan drug designation to CTD401, a chimeric antigen receptor T-cell therapy for the treatment of T-cell acute lymphoblastic leukemia, according to the agent’s manufacturer.

More than 80% of patients with relapsed or refractory multiple myeloma remained alive 18 months after receiving a single infusion of ciltacabtagene autoleucel, according to the latest results of a phase 1/phase 2 clinical trial.

Ninety-five percent of patients with relapsed or refractory T-cell acute lymphoblastic leukemia responded to therapy with donor-derived chimeric antigen receptor T cells, according to results of a phase 1 study.

The FDA lifted the clinical holds on four studies designed to evaluate two gene therapies for hematologic conditions.

Brexucabtagene autoleucel induced an overall remission rate of greater than 70% among adults with relapsed or refractory B-cell acute lymphoblastic leukemia who received a single infusion of the therapy, according to phase 2 study results.

Lisocabtagene maraleucel extended EFS and PFS compared with high-dose chemotherapy and hematopoietic stem cell transplant for relapsed or refractory large B-cell lymphoma, according to topline data released by the agent’s manufacturer.

What if the next paradigm shift in cancer treatment isn’t something new? What if it is something that has been on super-low burn for an entire generation?